Back

Lipid-siRNA conjugate accesses a perivascular transport mechanism and achieves widespread and durable knockdown in the central nervous system

Sorets, A.; Schwensen, K.; Francini, N.; Kjar, A.; Abdulrahman, A.; Shostak, A.; Katdare, K.; Schoch, K.; Cowell, R.; Park, J.; Ligocki, A.; Ford, W.; Ventura-Antunes, L.; Hoogenboezem, E.; Prusky, A.; Castleberry, M.; Michell, D. L.; Miller, T.; Vickers, K.; Schrag, M.; Duvall, C.; Lippmann, E.

2024-09-07 bioengineering
10.1101/2024.06.09.598079 bioRxiv
Show abstract

Short-interfering RNA (siRNA) has gained significant interest for treatment of neurological diseases by providing the capacity to achieve sustained inhibition of nearly any gene target. Yet, efficacious drug delivery throughout deep brain structures of the CNS remains a considerable hurdle for intrathecally administered therapeutics. We herein describe an albumin-binding lipid-siRNA conjugate that transports along meningeal and perivascular CSF pathways, leading to broad dispersion throughout the CNS parenchyma. We provide a detailed examination of the temporal kinetics of gene silencing, highlighting potent knockdown for up to five months from a single injection without detectable toxicity. Single-cell RNA sequencing further demonstrates gene silencing activity across diverse cell populations in the parenchyma and at brain borders, which may provide new avenues for neurological disease-modifying therapies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.